https://www.selleckchem.com/pr....oducts/fasoracetam-n
3%) patients in the PIPAC-Ox + 5-FU/L group (p=0.73). The complete histological response rates according to the peritoneal regression grading score were 27% for the PIPAC-Ox + 5-FU/L group and 18% for the PIPAC-Ox group (p=0.74). No statistically significant differences were observed in overall or progression-free survival between the two groups. The safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be
Like
Comment
Share
